Inclusion Criteria:  Male and female patients with age ≥18; subjects who are over 70 years of age must be in generally stable health conditions. There should be evidences that HBsAg has been positive for more than 6 months or HBV-related histological changes. Planned to receive or already receiving anti-viral treatment with nucleos(t)ide including Entecavir, Tenofovir, and Tenofoviralafenamide. Or planned to receive peginterferon alpha 2b, either treated or treatment-naive. Agree to participate in the study and sign the patient informed consent form.  Exclusion Criteria:  Currently treatment-related participating clinical trials.